TY  - JOUR
AU  - Rhee, Soo-Yon
AU  - Varghese, Vici
AU  - Holmes, Susan P
AU  - Van Zyl, Gert U
AU  - Steegen, Kim
AU  - Boyd, Mark A
AU  - Cooper, David A
AU  - Nsanzimana, Sabin
AU  - Saravanan, Shanmugam
AU  - Charpentier, Charlotte
AU  - de Oliveira, Tulio
AU  - Etiebet, Mary-Ann A
AU  - Garcia, Federico
AU  - Goedhals, Dominique
AU  - Gomes, Perpetua
AU  - Günthard, Huldrych F
AU  - Hamers, Raph L
AU  - Hoffmann, Christopher J
AU  - Hunt, Gillian
AU  - Jiamsakul, Awachana
AU  - Kaleebu, Pontiano
AU  - Kanki, Phyllis
AU  - Kantor, Rami
AU  - Kerschberger, Bernhard
AU  - Marconi, Vincent C
AU  - D'amour Ndahimana, Jean
AU  - Ndembi, Nicaise
AU  - Ngo-Giang-Huong, Nicole
AU  - Rokx, Casper
AU  - Santoro, Maria M
AU  - Schapiro, Jonathan M
AU  - Schmidt, Daniel
AU  - Seu, Lillian
AU  - Sigaloff, Kim C E
AU  - Sirivichayakul, Sunee
AU  - Skhosana, Lindiwe
AU  - Sunpath, Henry
AU  - Tang, Michele
AU  - Yang, Chunfu
AU  - Carmona, Sergio
AU  - Gupta, Ravindra K
AU  - Shafer, Robert W
PY  - 2017
DO  - 10.1016/j.ebiom.2017.03.024
UR  - http://hdl.handle.net/10668/11034
T2  - EBioMedicine
AB  - Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse...
LA  - en
KW  - Antiretroviral therapy
KW  - Drug resistance
KW  - HIV-1
KW  - Reverse transcriptase
KW  - Tenofovir
KW  - WHO-recommended first-line
KW  - Drug Resistance, Viral
KW  - Genotype
KW  - HIV Infections
KW  - HIV Reverse Transcriptase
KW  - HIV-1
KW  - Humans
KW  - Mutation
KW  - Prevalence
KW  - Reverse Transcriptase Inhibitors
KW  - Tenofovir
KW  - Treatment Failure
KW  - Viral Load
KW  - World Health Organization
TI  - Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
TY  - research article
VL  - 18
ER  -